ORIGINAL RESEARCH
Published on 18 Aug 2025
Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes
doi 10.3389/fimmu.2025.1586512
- 893 views